Hinge Health (HNGE) Financials

Hinge Health’s latest quarter shows a business that is growing revenue, generating solid operating cash flow, and holding a large cash position, but it is also still dealing with meaningful equity structure complexity and lumpy profitability. For retail investors, the big picture is that the company has moved from heavy losses in 2025 toward a much stronger operating profile in early 2026.

Revenue and profitability improved sharply year over year. Q1 2026 revenue rose to $182.3 million, up from $123.8 million in Q1 2025 and $154.2 million in Q3 2025. Gross profit was $154.2 million, producing a strong gross margin of about 84%, which suggests the core business model remains highly scalable.

Operating income returned to profitability in Q1 2026. The company posted $32.1 million in operating income and $34.0 million in net income attributable to common shareholders, compared with an operating loss in Q3 2025 and a much larger net loss in Q2 2025. That is a notable sequential and year-over-year turnaround.

Cash generation also looks healthy. Hinge Health produced $43.1 million in operating cash flow in Q1 2026, following $63.9 million in Q4 2025 and $82.4 million in Q3 2025. While quarterly cash flow can move around, the recent pattern shows the business is capable of generating meaningful cash from operations.

The balance sheet appears liquid. As of Q1 2026, the company reported $186.7 million in cash and equivalents and $129.2 million in short-term investments, plus $89.8 million in long-term investments. That gives Hinge Health a sizable cushion to fund operations and strategic investments.

Deferred revenue remains a support for future sales visibility. Current deferred revenue was $340.8 million in Q1 2026, up from $299.7 million in Q3 2025 and $275.1 million in Q2 2025. Rising deferred revenue can be a positive sign for subscription or service-based businesses because it indicates cash collected ahead of revenue recognition.

However, the company has a complex equity structure. Hinge Health carries a large redeemable noncontrolling interest of $199.9 million, which makes the ownership and capital structure more complicated than a typical growth company. Retail investors should keep this in mind when evaluating per-share value.

There are also signs of significant dilution and capital structure changes over time. Common stock on the balance sheet fell from $1.291 billion in Q3 2025 to $1.128 billion in Q1 2026, while retained earnings remained deeply negative at $(1.016) billion. That reflects the company’s long path from earlier losses and prior financing activity.

• Revenue growth accelerated: Q1 2026 revenue of $182.3 million was up meaningfully from prior quarters.
• Strong gross margin: Gross profit of $154.2 million on $182.3 million of revenue points to a very healthy margin profile.
• Back to operating profitability: Q1 2026 operating income was $32.1 million versus an operating loss in Q3 2025.
• Positive net income: Common shareholders earned $34.0 million in Q1 2026.
• Operating cash flow remained positive: The company generated $43.1 million from operations in the quarter.
• Large liquidity cushion: Cash plus investments totaled more than $405 million in Q1 2026.
• Deferred revenue increased: Current deferred revenue rose to $340.8 million, supporting future revenue recognition.
• Investment activity was significant: The company bought and sold large amounts of securities, which can affect quarter-to-quarter cash balances.
• Capital structure is complicated: Redeemable noncontrolling interest remains a large line item on the balance sheet.
• Shareholder equity is still modest relative to liabilities and structure complexity: Total common equity was only $111.7 million in Q1 2026.

Looking back across the last several quarters, Hinge Health’s trend is improving: Q2 2025 showed a very large loss, Q3 2025 was still unprofitable, Q4 2025 turned clearly positive on cash flow and earnings, and Q1 2026 showed continued operating strength. If that pattern holds, investors may start to view the company less as a turnaround story and more as a growing, cash-generative healthcare technology business.